Kymera Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Kymera Therapeutics, Inc. on June 15, 2022. The filing details the voting results for four proposals submitted to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Class II Directors): Stockholders elected Jeffrey Albers, J.D., MBA and Joanna Horobin, M.B., Ch.B. for three-year terms ending in 2025.
- Jeffrey Albers: 29,436,931 votes For; 9,840,519 votes Withheld.
- Joanna Horobin: 31,950,427 votes For; 7,327,023 votes Withheld.
- Proposal 2 (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Results: 33,866,486 votes For; 1,793,865 votes Against; 3,617,099 Abstain.
- Proposal 3 (Frequency of Say-on-Pay): Stockholders recommended an annual frequency for future advisory votes on executive compensation.
- Results: 35,557,849 votes for One Year; 1,826 votes for Two Years; 128,751 votes for Three Years.
- Proposal 4 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Results: 38,429,952 votes For; 22,711 votes Against; 3,623,430 Abstain.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. The Board of Directors determined to hold annual advisory votes on executive compensation based on the results of Proposal 3.
Key Facts for Investor Verification
- Confirmation of the new Class II directors' terms ending in 2025.
- Verification of the annual frequency for future Say-on-Pay votes.
- Confirmation that Ernst & Young LLP is the appointed auditor for the 2022 fiscal year.
- Review of the Proxy Statement filed on April 29, 2022, for detailed background on the proposals.